Organon Returns Ebopiprant to XOMA
27. Oktober 2023 17:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
14. Dezember 2022 07:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
14. Dezember 2022 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
22. November 2022 07:00 ET
|
ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
22. November 2022 01:00 ET
|
ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
05. August 2021 01:00 ET
|
ObsEva SA
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Linzagolix for endometriosis:...
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
27. Juli 2021 01:00 ET
|
ObsEva SA
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i; agent is being studied in an area of significant unmet need Ad hoc...
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
02. Juli 2021 01:00 ET
|
ObsEva SA
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia– GENEVA, Switzerland and BOSTON – July 2,...
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
10. Juni 2021 01:00 ET
|
ObsEva SA
-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation- - Phase 2b/3 adaptive dose-ranging study planned to initiate in Q4:21- ...
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
02. Juni 2021 01:00 ET
|
ObsEva SA
- Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation - GENEVA, Switzerland and BOSTON, MA – June 2, 2021 –...